Compugen Ltd. (CGEN)Healthcare | Biotechnology | Holon, Israel | NasdaqCM
1.98 USD
-0.09
(-4.348%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
After hours: 2.01 +0.03 (1.515%) ⇧ (Oct. 13, 2026, 6:38 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 7:40 a.m. EDT
The investment thesis here rests entirely on the massive gap between current reality and analyst expectations. Fundamentally, the company is showing signs of life with a 107% revenue surge and a royalty deal with AstraZeneca, yet the stock trades at a fraction of its implied value based on a $4.60 mean target. The balance sheet is pristine with negligible debt and strong cash flow, allowing management to pivot without immediate existential pressure. However, the long-term rating is capped at 3.5 because the price history tells a brutal story of volatility and destruction; the stock has lost nearly 71% of its value over the last nine years, indicating that the market has deeply punished this business repeatedly. While the latest year saw a recovery, the legacy of multi-year declines weighs heavily on the valuation multiple. Short-term, the setup is intriguing but risky. The options market is screaming 'call,' with heavy positioning in OTM strikes, suggesting traders are waiting for a specific clinical or commercial catalyst to ignite a move. Yet, the statistical forecast model offers almost no guidance, labeling the upcoming 45-day outlook as a weak lean with low confidence. This disconnect—strong fundamental momentum and aggressive options buying versus a flat statistical forecast—suggests the stock is currently priced for a binary event. Until that catalyst hits, the path remains choppy, justifying a cautious stance rather than a full conviction entry. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.073890 |
| AutoARIMA | 0.082769 |
| AutoETS | 0.082925 |
| MSTL | 0.123024 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 1.39 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.018 |
| Excess Kurtosis | 0.64 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3.407 |
| Revenue per Share | 0.785 |
| Market Cap | 187,553,808 |
| Trailing P/E | 5.21 |
| Forward P/E | -5.40 |
| Beta | 2.79 |
| Profit Margins | 47.55% |
| Website | https://cgen.com |
As of Oct. 10, 2026, 7:40 a.m. EDT: Speculators are overwhelmingly bullish on upside potential, evidenced by significant open interest in out-of-the-money calls (strikes $5.00) compared to virtually zero put activity. This asymmetry suggests a bet on a catalyst-driven rally rather than a hedge against downside risk.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.0048543215 |
| Address1 | Azrieli Center |
| Address2 | Building D 26 Harokmim Street |
| All Time High | 19.9 |
| All Time Low | 0.34 |
| Ask | 2.54 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 164,110 |
| Average Daily Volume3 Month | 242,879 |
| Average Volume | 242,879 |
| Average Volume10Days | 164,110 |
| Beta | 2.789 |
| Bid | 1.5 |
| Bid Size | 2 |
| Book Value | 0.937 |
| City | Holon |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | Israel |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.98 |
| Current Ratio | 5.718 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 2.09 |
| Day Low | 1.96 |
| Debt To Equity | 3.407 |
| Display Name | Compugen |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,760,200 |
| Earnings Call Timestamp Start | 1,785,760,200 |
| Earnings Timestamp | 1,785,760,200 |
| Earnings Timestamp End | 1,794,227,400 |
| Earnings Timestamp Start | 1,794,227,400 |
| Ebitda | 30,676,000 |
| Ebitda Margins | 0.41452998 |
| Enterprise To Ebitda | 2.128 |
| Enterprise To Revenue | 0.882 |
| Enterprise Value | 65,276,808 |
| Eps Current Year | -0.33 |
| Eps Forward | -0.36667 |
| Eps Trailing Twelve Months | 0.38 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 972 3 765 8555 |
| Fifty Day Average | 2.4358 |
| Fifty Day Average Change | -0.45580006 |
| Fifty Day Average Change Percent | -0.1871254 |
| Fifty Two Week Change Percent | 0.48543215 |
| Fifty Two Week High | 3.24 |
| Fifty Two Week High Change | -1.26 |
| Fifty Two Week High Change Percent | -0.3888889 |
| Fifty Two Week Low | 1.43 |
| Fifty Two Week Low Change | 0.5500001 |
| Fifty Two Week Low Change Percent | 0.38461545 |
| Fifty Two Week Range | 1.43 - 3.24 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 966,000,600,000 |
| Float Shares | 94,511,964 |
| Forward Eps | -0.36667 |
| Forward P E | -5.399951 |
| Free Cashflow | 22,217,000 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 75 |
| Fullday Change | -0.059999943 |
| Fullday Change Percent | -2.8985481 |
| Fullday Price | 1.98 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.86887 |
| Gross Profits | 64,297,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00202 |
| Held Percent Institutions | 0.1522 |
| Implied Shares Outstanding | 94,724,146 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://cgen.com/investors |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. The company was incorporated in 1993 and is headquartered in Holon, Israel. |
| Long Name | Compugen Ltd. |
| Market | us_market |
| Market Cap | 187,553,808 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_166115 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 35,191,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 232,607,437 |
| Number Of Analyst Opinions | 5 |
| Open | 2.08 |
| Operating Cashflow | 28,251,000 |
| Operating Margins | -3.3962297 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.29 |
| Phone | 972 3 765 8585 |
| Post Market Change | 0.029999971 |
| Post Market Change Percent | 1.5151501 |
| Post Market Price | 2.01 |
| Post Market Time | 1,791,931,117 |
| Previous Close | 2.07 |
| Price Eps Current Year | -6.0 |
| Price Hint | 4 |
| Price To Book | 2.113127 |
| Price To Sales Trailing12 Months | 2.5344768 |
| Profit Margins | 0.47555 |
| Quick Ratio | 5.718 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.0899999 |
| Regular Market Change Percent | -4.34782 |
| Regular Market Day High | 2.09 |
| Regular Market Day Low | 1.96 |
| Regular Market Day Range | 1.96 - 2.09 |
| Regular Market Open | 2.08 |
| Regular Market Previous Close | 2.07 |
| Regular Market Price | 1.98 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 223,384 |
| Return On Assets | 0.15464 |
| Return On Equity | 0.50638 |
| Revenue Growth | 1.07 |
| Revenue Per Share | 0.785 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 94,724,146 |
| Shares Percent Shares Out | 0.0249 |
| Shares Short | 2,354,274 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 2,349,292 |
| Short Name | Compugen Ltd. |
| Short Percent Of Float | 0.0249 |
| Short Ratio | 13.67 |
| Source Interval | 15 |
| Symbol | CGEN |
| Target High Price | 6.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 4.6 |
| Target Median Price | 4.0 |
| Total Cash | 125,300,000 |
| Total Cash Per Share | 1.323 |
| Total Debt | 3,023,000 |
| Total Revenue | 74,001,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.38 |
| Trailing P E | 5.2105265 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.27335 |
| Two Hundred Day Average Change | -0.29334998 |
| Two Hundred Day Average Change Percent | -0.12903863 |
| Type Disp | Equity |
| Volume | 223,384 |
| Website | https://cgen.com |
| Zip | 5,885,849 |